Hospor Hospitais Portugueses S.A.
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
At Hospor Hospitais Portugueses S.A. in Setubal, clinical research in cardiology focuses strongly on cardiovascular diseases, especially heart failure, hypertension, and broader high cardiovascular risk populations. These trials are designed to test new treatment approaches and better understand how to reduce serious heart-related events and improve outcomes for patients with complex cardiac conditions.
- Evaluating therapies for heart failure in patients with preserved or mildly reduced ejection fraction
- Studying treatments aimed at lowering cardiovascular risk and preventing major heart events
- Assessing options for people with hypertension and established heart disease
Overall, this area reflects a clear emphasis on improving treatment effectiveness for patients with advanced or high-risk cardiovascular conditions.
Oncology Clinical Trials
The site also contributes to neoplasm research, with a focus on early breast cancer that is node-positive, estrogen receptor-positive, and HER2-negative. This work is aimed at comparing new treatment strategies with current standard care to help improve long-term cancer control and reduce the chance of recurrence.
- Testing a new therapy against standard endocrine treatment in early breast cancer
- Supporting research in patients with a higher risk of cancer recurrence
- Exploring ways to improve invasive breast cancer-free survival
This oncology portfolio highlights the hospital’s involvement in advancing care for selected breast cancer populations through comparative treatment research.
Respiratory Disease Studies
Research in respiratory tract diseases includes studies in chronic obstructive pulmonary disease, with attention to inflammatory pathways that may influence symptoms and disease control. These trials are intended to evaluate new biologic approaches and improve the management of patients living with chronic lung disease.
- Investigating treatment options for COPD with type 2 inflammation
- Assessing whether new therapies can better control chronic lung inflammation
- Looking for improved ways to support long-term respiratory health
At this Portuguese hospital, respiratory research adds another important dimension to a trial program that spans both heart and lung disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospor Hospitais Portugueses S.A.
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation. | Glaxosmithkline Research & Development Limited | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 1 | Unknown | 2025-03-24 | 2025-03-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.